Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on Apellis Pharmaceuticals (NASDAQ:APLS) and lowers the price target from $57 to $48.
May 23, 2024 | 2:27 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on Apellis Pharmaceuticals and lowers the price target from $57 to $48.
The lowered price target from $57 to $48 by Wells Fargo suggests a less optimistic outlook for Apellis Pharmaceuticals, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100